Head-to-head evidence
GW642444H vs Olodaterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
GW642444H
Developed by GlaxoSmithKline
NCT00381667 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, but enrolled only 14 participants. Its primary outcomes included lung-function and safety measurements rather than a hard clinical endpoint, and the primary comparison cannot be assessed because results have not been posted.
Olodaterol
Marketed by Boehringer Ingelheim
NCT00467740 · Phase 2 · completed
The study randomized 296 participants to placebo or one of four olodaterol doses, but the registry does not clearly report whether treatment assignment was blinded. Its primary outcome was a lung-function surrogate rather than a hard clinical outcome, and results were mixed across doses: only olodaterol 20 micrograms significantly improved trough FEV1 versus placebo at 4 weeks.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GW642444H's landscape · Olodaterol's landscape